Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc. was a clinical-stage precision oncology company whose updates centered on oncology drug programs, portfolio partnerships, and corporate-status developments. Recurring news included clinical disclosures for RP-1664, an oral PLK4 inhibitor studied in TRIM37-high solid tumors in the LIONS trial, and RP-3467, a Polθ ATPase inhibitor evaluated in the POLAR trial. Other updates covered the lunresertib PKMYT1 inhibitor license, out-licensing of discovery platforms, operating results, capital-structure matters, governance, and the completed acquisition and related delisting process.
Repare Therapeutics Inc. (Nasdaq: RPTX) announced that its CEO, Lloyd M. Segal, will engage in a fireside chat during the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020. The discussion will be available for replay on the company’s website in the Investor section for 90 days. Repare specializes in precision oncology using its SNIPRx® platform to develop innovative cancer therapies focusing on genomic instability. Key products include the ATR inhibitor RP-3500 and CCNE1-SL inhibitor programs.
Repare Therapeutics (RPTX) reported Q3 2020 financial results, showcasing significant advancements in its oncology pipeline. The company entered a Phase 1/2 trial for RP-3500 in July and anticipates launching a Phase 1 trial for RP-6306 ahead of schedule in Q3 2021. Cash and restricted cash stood at $348.1 million. R&D expenses rose to $10.1 million for Q3, predominantly due to the RP-3500 and RP-6306 programs. G&A expenses increased to $4.0 million, reflecting public company operational costs. The net loss for Q3 was $13.8 million, translating to $0.37 per share.